Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: Evidence from a routine therapeutic drug monitoring service

Therapeutic Drug Monitoring

Volumn 27, Issue 1, 2005, Pages 103-106

  Castberg, Ingrid ^a   Spigset, Olav ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Intramuscular administration; Pharmacokinetics; Risperidone; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; LEVOMEPROMAZINE; LONG ACTING DRUG; PALIPERIDONE; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG MONITORING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADMINISTRATION, ORAL; ADULT; AGED; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA;

EID: 13244291285     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200502000-00019     Document Type: Article

References (15)

1. Barnes TR, Curson DA. Long-term depot antipsychotics: a risk-benefit assessment. Drug Saf 1994;10:464-479.
2. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry. 1995;40(3, suppl. 1):S5-S11.
3. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300-307.
4. Harrison TS, Goa KL. Long-acting risperidone. A review of its use in schizophrenia. CNS Drugs. 2004;18:113-132.
5. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001;29:1263-1268.
6. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A4. J Clin Psychiatry. 1999;60:469-476.
7. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999;147:300-305.
8. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22:481-485.
9. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001;23:223-227.
10. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol. 2002;22:419-423.
11. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl). 2002;162:50-54.
12. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl). 2001;153:238-243.
13. Olesen OV, Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20:380-384.
14. Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit. 1994;16:1-12.
15. Llerena A, Bercez R, Dorado P, et al. Determination of risperidone and 9-hydroxyrisperidone in huma plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;783:213-219.